Objectives: Iclaprim is a novel 2,4-diaminopyrimidine that exhibits potent, rapid bactericidal activity against major Gram-positive pathogens, including methicillin-susceptible Staphylococcus aureus and methicillin-resistant S. aureus, and is currently in clinical development for the treatment of complicated skin and skin structure infections. An understanding of the known mechanism of resistance to trimethoprim led to the design of this new inhibitor, with improved affinity towards dihydrofolate reductase (DHFR) from S. aureus and clinically useful activity against S. aureus including isolates resistant to trimethoprim. The objective of this study was to characterize the mode of action of iclaprim and its inhibitory properties against DHFR.
Introduction
Dihydrofolate reductase (DHFR) (EC 1.5.1.3.) catalyses the transfer of a hydride ion from nicotinamide adenine dinucleotide phosphate (NADPH) to 7,8-dihydrofolate (DHF), forming the product 5,6,7,8-tetrahydrofolate (THF). DHFR is a key enzyme in the THF synthesis pathway, as it is essential for maintaining the intracellular pools of THF and its derivatives, which are essential cofactors in a number of one-carbon transfer reactions including those involved in the biosynthesis of thymidylate, methionine, purine nucleotides, pantothenate and other metabolites. 1 Inhibition of this enzyme arrests DNA synthesis and cell division, leading to cell death. Due to its central role in these critical cellular functions, DHFR has been the target for small molecule therapeutics in the treatment of cancer as well as bacterial and parasitic infections. 1 -3 As a consequence of its importance, a wealth of information has been generated on the structure, mechanism and inhibition of DHFR from human, parasitic, fungal and bacterial sources.
Trimethoprim (2,4-diamino-5-[3,4,5-trimethoxybenzyl]-pyrimidine; Figure 1 ) is a clinically important inhibitor of bacterial DHFR. It has been described as a competitive inhibitor of DHFR, with greatly increased potency towards the bacterial enzymes. 5 Due to this selectivity over the human DHFR, trimethoprim, either alone or in combination with sulfamethoxazole, has been widely used in the clinic as a treatment for community-acquired (CA) infections, particularly of the urinary and respiratory tracts, with emphasis on those caused by Gram-negative pathogens. In addition, the highly synergistic trimethoprim/sulfamethoxazole combination is also active against bacteria resistant to many other classes of antibiotics and has thus been useful in the treatment of staphylococcal infections 6 and has been employed in the clinic to treat infections caused by multidrug-resistant staphylococci such as methicillin-resistant Staphylococcus aureus (MRSA). 7 The use of trimethoprim/sulfamethoxazole has recently been suggested as an appropriate choice for outpatient empirical therapy of suspected S. aureus skin and skin structure infections, especially when the prevalence of MRSA and CA-MRSA in the patient population is significant, 8 even though this indication is not part of the drug label. However, concerns have been raised against the empirical use of trimethoprim/sulfamethoxazole for treating Gram-positive skin infections, in particular: (i) safety issues associated with sulfamethoxazole; 9 (ii) the low efficacy in treating skin infections caused by Streptococcus pyogenes, a key causative pathogen; 10 and (iii) the large difference in the pharmacokinetic properties of the two components, which may compromise the achievement of the best synergistic ratio of trimethoprim/sulfamethoxazole at the infection site. 11 Antimicrobial resistance, in both hospitals and the community, is a clinically important and ever increasing problem. 12, 13 Of particular concern are the MRSA strains that harbour resistance against many other antibiotic classes currently in clinical use. 14, 15 Before the early 1980s, resistance to trimethoprim and trimethoprim/sulfamethoxazole was fairly uncommon, with 1% to 6% of the S. aureus isolates reported as resistant. 16 Although there is regional variation in trimethoprim and trimethoprim/sulfamethoxazole resistance among MRSA isolates, 17 recent US surveillance studies showed that trimethoprim/sulfamethoxazole remains among the drugs with the lowest resistance rates, in over 380 000 S. aureus isolates tested. 18 The mechanism of resistance against trimethoprim has been clarified through genetic studies. Three transposons or plasmid-encoded trimethoprim-resistant DHFR isoforms have been identified in staphylococci: the S1, S2 and S3 enzymes encoded by the dfrA, dfrD and dfrG genes, respectively. 19 -21 Only the strains with an MIC of trimethoprim !256 mg/L carry these genetic elements and have proved to be rare. 22, 23 However, trimethoprim-resistant strains with an MIC of trimethoprim ,256 mg/L are less rare and were all shown to contain a mutation in the chromosomal gene. It was determined that a single point mutation in the DHFR enzymes, be it transposon, plasmid or chromosomally encoded, is responsible for the reduced susceptibility of staphylococci to trimethoprim. 22, 23 For example, the single mutation from Phe to Tyr in the S. aureus strain B71 (F98Y), a clinical isolate from Germany, resulted in a 64-fold increase in the MIC of trimethoprim for the strain. 23 This mutation resulted in the loss of a single hydrogen bond between the 4-amino group of trimethoprim and the enzyme. The resulting decrease in affinity was identified as the mechanism of resistance at the protein level. 23 Understanding the known mechanism of resistance to trimethoprim led to the design of iclaprim, a new inhibitor with improved affinity towards the S. aureus DHFR. Iclaprim {5-[(2RS)-2-cyclopropyl-7,8-dimethoxy-2H-chromene-5-ylmethyl]pyrimidine-2,4-diamine; formerly AR-100; Figure 1} is a novel 2,4-diaminopyrimidine that exhibits potent, rapid bactericidal activity against major Gram-positive pathogens, including methicillin-susceptible S. aureus, MRSA and F98Y trimethoprim-resistant strains. Moreover, iclaprim demonstrates a good distribution in tissues and organs and is safe and well tolerated. 24 Iclaprim specifically and selectively inhibits bacterial DHFR at submicromolar concentrations with no inhibition of the human enzyme at over five orders of magnitude higher concentrations. 25 Iclaprim maintained clinically useful activity towards S. aureus, including those strains resistant to trimethoprim. Iclaprim has been tested in Phase III clinical trials for the treatment of complicated skin and skin structure infections. The purpose of this study was to characterize the mode of action of iclaprim and its inhibitory properties.
An understanding of the molecular mechanism of trimethoprim resistance in S. aureus led to the design and characterization of this new inhibitor with improved affinity towards the S. aureus DHFR.
Materials and methods

PCR and protein expression
The genes encoding DHFR from S. aureus ATCC 25923 and S. aureus 101 were amplified by PCR, cloned as N-terminal 6-His-tagged proteins using the pQE30 expression vector following the protocol described by the manufacturer (Qiagen). The primers used for PCR amplification of the genes were: 5 0 -GACGGATCCC ATATGACTTTATCCATTCTAGTTGCACA-3 0 and 5 0 -GACGGATC CTTAAAGCTTTTTTTTACGAATTAAATGTAGAAAGGTATG-3 0 . Proteins were expressed in Escherichia coli, M15 ( pRep4), was the expression host. Cells were grown in lysogeny broth (LB) medium containing 100 mg/L ampicillin and 25 mg/L kanamycin, and DHFR protein expression was induced by the addition of 1 mM IPTG. The expression and purification of the F98Y mutant DHFR have been described previously. 23 
DHFR activity assays
The in vitro DHFR assay was performed as described previously. 22 DHFR activities were determined using a PowerWave TM HT spectrophotometer. All reactions were performed in a 1 mL reaction volume in a 1 mL Bio-cell with 50 mM Tris-HCl, pH 7.5, 50 mM NaCl, 1 mM EDTA, 10 mM b-mercaptoethanol, 50 mM DHF, 100 mM reduced NADPH and the appropriate amount of bacterial Oefner et al. Control experiments included injections of dimethyl sulphoxide (DMSO) into the buffer to account for the heats of dilution of DMSO under identical conditions. Raw data (mcal/s) for each injection were integrated to give the total heat effect per addition and then divided by the amount of injectant to give kcal/ mole of the injectant. The same integration was applied for control dilution effects, and this was subtracted from the actual titration data. This provided a differential of the binding curve, in which the extent of binding is proportional to the heat liberated (or absorbed). The data were then analysed using fits of single-binding site models. Analysis of changes in the heat accompanying inhibitor binding allowed us to derive the binding enthalpy of the processes (DH), to estimate the stoichiometry (n) and association constants (K a ). The entropy of the binding reactions (DS) and the free energy change (DG) were obtained from the relation DG ¼ 2RT ln(K a )¼ DH2TDS.
Crystallography and structural studies
Crystals of the trimethoprim-sensitive and trimethoprim-resistant F98Y single mutant DHFR from S. aureus were obtained in the presence of 2 mM NADPH and 6 mM folate, using the hanging drop vapour diffusion method. 26 Hexagonal bi-pyramidal crystals grew from protein solutions of $30 mg/mL in 25% PEG 3350, 200 mM NaCl and 100 mM bis -Tris, pH 5.5. Although these conditions differ from those published previously, 23 the proteins crystallized in an identical fashion in the hexagonal space group P6 1 22 and contain one molecule in the asymmetric unit. Trimethoprim and iclaprim, dissolved in DMSO, were added to the mother liquor at concentrations of 2 and 1.4 mM, respectively, and crystals of the wild-type and mutant enzyme were soaked for $4 h. The final DMSO concentration was 5%. Prior to data collection, the crystals were flash frozen at 100 K. Diffraction intensities were measured with CuKa radiation obtained from a Nonius FR591 rotating anode equipped with an Osmic mirror system and were recorded on an MAR Research image-plate area detector. All diffraction data were processed and scaled with DENZO and SCALEPACK and analysed further using the CCP4 program suite.
27, 28 The structure was solved by replacement using the coordinates of S. aureus DHFR complexed with folate. 23 Density fitting was performed with the graphics program MOLOC; 29 REFMAC 30 was used for stereochemically restrained positional and temperature-factor refinement, using parameters for ideal stereochemistry as described previously. 
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Synergy assay
Synergy testing was performed using the chequerboard assay, allowing multiple test concentrations of iclaprim and trimethoprim to be assayed in the presence of various concentrations of sulfamethoxazole. The fractional inhibitory concentration index ( P FIC) was calculated using the following formula: FIC A þFIC B ¼ P FIC, where FIC A ¼ MIC of iclaprim in combination/MIC of iclaprim alone and FIC B ¼ MIC of drug B in combination/MIC of drug B alone. Synergy was defined whereby the P FIC was 0.5.
Determination of MIC
MICs were determined following the standard CLSI protocol, 37 using 22 doubling dilutions of iclaprim, trimethoprim and 3 H]N-acetylglucosamine (12.5 mCi/mL with 41.7 mg/L unlabelled N-acetylglucosamine). The incorporation of radiolabelled precursors was blocked at different timepoints by the addition of 50% (w/v) trichloroacetic acid (TCA). TCA-precipitated material was collected on Millipore Multiscreen w Harvest FC filter plates by using a cell harvester, and radioactivity was determined in a plate scintillation counter.
Results and discussion
The kinetic properties of iclaprim and trimethoprim were compared against three S. aureus enzymes, the wild-type chromosomal DHFR, the trimethoprim-resistant single mutant F98Y DHFR and the clinical isolate MRSA 101 DHFR (H30N,  F98Y) . A comparison of the kinetic data is given in Table 1 . The Michaelis -Menten constants for DHF were similar to those previously published for these enzymes. 23 Equally, the IC 50 and K i values for trimethoprim were comparable to published values against all enzymes tested. 25 Both iclaprim and trimethoprim exhibit a competitive mode of inhibition towards the S. aureus wild-type and F98Y enzymes (Figure 2 ). Iclaprim has a 20-, 16.7-or 28.9-fold increase in affinity towards the various enzymes when compared with trimethoprim. When comparing the K i value for trimethoprim, a 16.7-and 43.3-fold decrease in affinity is observed between the wild-type and the F98Y enzyme and the wild-type and the 101 enzyme, respectively. This loss of affinity of trimethoprim for the mutant DHFR was shown to be due to the loss of a single hydrogen bond from the 4-amino group of trimethoprim towards the protein. 23 For iclaprim, the decrease in affinity is 20-and 30-fold for the mutant enzymes compared with the wildtype. Using the K i values determined here, the net loss in the binding energy is 2DDG ¼ RTln(K i mut /K i wild-type ), equivalent to 21.76 and 21.99 kcal/mol for the F98Y and MRSA 101 enzymes, respectively. The relative decrease in binding energy is similar for both inhibitors towards the mutant enzymes. These data suggest that the decrease in the activity of iclaprim towards the mutant enzyme is also due to the loss of a hydrogen bond, as observed for trimethoprim. Comparison of the differences in K i of trimethoprim and iclaprim against the staphylococcal enzymes shows that iclaprim is 20-, 16.7-and 28.9-fold more active against the wild-type, F98Y and MRSA 101 DHFR, respectively. The difference in binding energy can be calculated as 21.76, 21.65 and 21.97 kcal/mol for the wild-type, F98Y and MRSA 101 enzymes, respectively. This implies that the binding energy released during binding with the mutant enzyme is gained elsewhere in the molecule and that this is the mechanism through which iclaprim overcomes trimethoprim resistance. This is further supported by additional ITC studies. Apparent association constants and the free energy of inhibitor binding were determined using ITC. Analysis of changes in the heat-accompanying inhibitor binding to protein allowed us to derive the binding enthalpy of the processes (DH), to estimate the stoichiometry (n) and association constants (K a ) and, furthermore, to calculate the entropy (DS) and free energy (DG) of the binding reactions. Figure 3 shows the calorimetric titration for iclaprim and trimethoprim to the staphylococcal enzymes. The thermodynamic characteristics are shown in Table 2 . Binding of both iclaprim and trimethoprim is exothermic with negative changes in enthalpy. The apparent binding constants are below 1 nM for both iclaprim and trimethoprim towards the wild-type enzyme, where ITC titrations lose their curvature and are thus below the limit for accurate measurement. The high affinity of both inhibitors towards the wild-type enzyme is similar to that observed in enzyme kinetic experiments. In order to obtain accurate K a values for these tight binding inhibitors, competition (8) 1.14 0.9 1.28 1.14 1.32
, where I i (h) and ,I(h). are the ith and mean measurements of the intensity of reflection h. b P h kF obs j2jF calc k/ P h jF obs j, where jF obs j and jF calc j are the observed and calculated structure factor amplitudes for reflection h, applied to the working (R cryst ) and test (R free ) sets, respectively. c rmsd, root mean square deviation from mean.
experiments will need to be conducted. 39 Compared with trimethoprim, a 13-fold increase in the association constant of iclaprim towards the F98Y enzyme was observed, for which a difference in DG of 21.88 kcal/mol is calculated. This result is in good agreement with the kinetic data.
To understand the structural basis of the increased affinity of iclaprim towards the S. aureus enzymes, we determined the X-ray structure of iclaprim in the wild-type and F98Y enzymes. For comparison, we also determined the X-ray structure of the wild-type and F98Y enzymes in the presence of NADPH and trimethoprim, as well as the structure of the ternary complex of the wild-type DHFR in the presence of folate and NADPH (Table 3 ). All structures were determined in the presence of NADPH and thus represent ternary complexes. The observed interaction of TMP with the wild-type S. aureus enzyme is consistent with that reported. 23 The 2,4-diamino pyrimidine (DAP) moiety of trimethoprim interacts via an ionic interaction between the 2-amino group and N1 of DAP with the side chain of D27. The amino group in position 4 is within hydrogen bonding distance to the carbonyl oxygen of L5 and F92 at $2.7 Å (Figure 4) .
The activities of trimethoprim and iclaprim against the wild-type and F98Y DHFR enzymes are affected by structural features of the substrate-binding pocket. The DAP moiety of iclaprim binds to the wild-type enzyme in a manner identical to that observed for trimethoprim (Figure 4, top) . The trimethoxy phenyl moiety of trimethoprim and the dimethoxy chromene moiety of iclaprim, however, are positioned slightly differently within the hydrophobic channel of the enzyme, which is formed by residues L20, L28, V31, I50 and L54. The binding motif of the DAP moiety of iclaprim and that of trimethoprim to the F98Y enzyme, however, are different (Figure 4, bottom) . The mutation F98Y introduces a hydroxyl functionality interacting with the main-chain carbonyl oxygen of L5, thus rendering it unavailable for hydrogen bonding to the ligand. The loss of this hydrogen bond has been described as the mechanism of resistance against trimethoprim. 23 The DAP moiety of iclaprim is shifted towards the carbonyl of L5 by $0.2 Å , resulting in a slightly different location of the dimethoxy chromene moiety within the hydrophobic channel of the enzyme. The net loss of binding energy through the disruption of a hydrogen bond at the 4-amino group of trimethoprim has been estimated to be $9.6 kJ/mol (2.3 kcal/mol) by comparing the E. coli and chicken DHFR -trimethoprim complexes. 40 accounts for $1.9 kcal/mol. Using the K i values obtained for the S. aureus wild-type and F98Y enzymes, the net loss of binding energy has been calculated to be 21.65 and 21.76 kcal/mol for trimethoprim and iclaprim, respectively, which is in good agreement with the predicted values. Taken together, these data suggest that the loss of a hydrogen bond is responsible for the decreased activity of both trimethoprim and iclaprim towards the mutant enzymes.
In light of the above, the increased binding affinity of iclaprim must be a result of the interactions of the dimethoxy chromene moiety with the target enzymes. The trimethoxy phenyl substituent of trimethoprim and the dimethoxy chromene side chain of the R and S enantiomer of iclaprim are situated in the hydrophobic channel of the enzymes formed by the side chains of residues L20, L28, V31, I50 and L54 (Figure 5a ). The increased size of the dimethoxy chromene substituent of iclaprim compared with the trimethoxy phenyl side chain of trimethoprim leads to an enlarged hydrophobic contact surface area with the protein, as well as with the nicotinamide moiety of NADPH by $39 Å 2 for the R and 35 Å 2 for the S enantiomer. This difference in the hydrophobic interface area between the dimethoxy chromene and trimethoxy phenyl substituents of the DAP warhead translates into $1.0-1.6 kcal/mol, using typical values for hydrophobic interactions. 41 This value fits well with the calculations from the kinetic data comparing trimethoprim and iclaprim, where the difference in the binding energy is calculated to be between 21.76 and 21.65 kcal/mol for wild-type and F98Y DHFR, respectively. The improved affinity of iclaprim towards the S. aureus enzymes as a result of increased hydrophobic interactions enables the molecule to efficiently inhibit the trimethoprim-resistant enzymes. In effect, iclaprim balances the loss and increase of affinity in such a way that it interacts with the mutant enzymes with the same affinity as trimethoprim does with the wild-type proteins, thereby overcoming the mechanism of resistance, which is reflected in its antibacterial activity ( Table 4) .
The increased binding energy of iclaprim through hydrophobic interactions occurs in an area of the enzyme important for substrate binding. Comparison of the NADPH ternary complexes of wild-type S. aureus DHFR with folate and iclaprim reveals that the p-aminobenzamide moiety of folate adopts a position within the hydrophobic channel of the enzyme, formed by the side chains of residues L20, L28, V31, I50 and L54, which is similar to that of the dimethoxy chromene moiety of iclaprim (Figure 5b ). This region is highly conserved and is composed of hydrophobic residues in all DHFR enzymes. Thus, it is reasonable to postulate that the potential for developing mutants resistant to iclaprim is limited, as the hydrophobic nature of the binding site has to be maintained intact for substrate binding. So far, no mutations leading to drug resistance have been identified in this region of the DHFR molecule. Thus, the binding of iclaprim to this region confers two advantages: increased affinity for its target and a lower likelihood of mutations leading to resistance. Biochemical and X-ray crystallographic data suggest that the increased activity of iclaprim on S. aureus is a direct result of DHFR enzyme inhibition. It has been known for many years that the in vitro antimicrobial activity of antifolates such as trimethoprim and sulfamethoxazole against various organisms is inhibited by high thymidine concentrations present in commercially prepared media. 42 More specifically, Hamilton-Miller and Stewart 43 reported that the antimicrobial activity of trimethoprim against the different species of Gram-positive cocci was reduced by the addition of thymidine (0.03 mg/mL) and that the susceptibility of the organisms decreased .500-fold. One of the predominant effects of DHFR inhibition is the cessation of the synthesis of endogenous thymidylate via thymidylate synthase. 44 Thus, the reversal of trimethoprim inhibition by the addition of thymidine is to be expected and is, in fact, the hallmark of an inhibitor of DHFR as it would circumvent the need for THF in the production of thymidylate by using thymidine kinase of the salvage pathway. 45 Table 5 shows the antimicrobial activities of trimethoprim and iclaprim and the reversal of inhibition by the addition of thymidine to the medium (Mueller -Hinton broth). As expected, both iclaprim and trimethoprim behave in a similar manner, as the antibacterial effects were reversed by the addition of thymidine to the medium.
Most bacteria do not have the enzymatic machinery to incorporate preformed folates and rather depend totally on the endogenous synthesis. One exception is Enterococcus, as it has been shown that some species of enterococci can use preformed folates, and the addition of folates to the medium can partially reverse the inhibitory effect of trimethoprim. 43, 46 Hamilton-Miller reported that the addition of folinic acid had a moderate effect on the susceptibility of E. faecium, showing a 10-fold decrease in trimethoprim susceptibility. Table 5 shows the effects of folinic acid addition on the MIC of both iclaprim and trimethoprim, resulting in 8-and 16-fold increases in MIC values, respectively. This result is similar to the previously reported data for trimethoprim. 43 Moreover, the effect of folinic acid on the antimicrobial properties of iclaprim is similar to that reported for trimethoprim.
A unique feature of antibacterial DHFR inhibitors, such as trimethoprim, is the synergy observed with sulphonamide compounds. 47 Sulphonamide antibiotics are p-aminobenzoic acid analogues that inhibit dihydropteroate synthase, an essential enzyme in the folate biosynthetic pathway. 48 We tested for synergy of iclaprim and trimethoprim with S. aureus ATCC 25293 and S. aureus clinical isolate MRSA 101 with respect to sulfamethoxazole ( Table 4) . As expected for a DHFR inhibitor, synergy was observed for sulfamethoxazole. No synergy was observed with any other antibiotics tested. 49 The major consequence of trimethoprim inhibition is a drastic and rapid reduction in the levels of THF, resulting in the depletion of the molecular components that are required by the bacterial cell for the synthesis of purines, pyrimidines, certain amino acids and N-formylmethionyl-tRNA for the initiation of protein synthesis. It has been observed that addition of trimethoprim to a growing bacterial culture results in the preferential inhibition of DNA, followed by RNA and protein syntheses. We have compared the inhibitory properties of iclaprim with trimethoprim using various assays. The effects of iclaprim on bacterial physiology suggest that this compound behaves as a classical antibacterial DHFR inhibitor, as defined by trimethoprim. The MMS profile, the reversion of inhibition by thymidine and folinic acid, as well as the synergy observed with sulphonamide inhibitors, was indistinguishable between iclaprim and trimethoprim. Direct enzyme binding and X-ray crystallographic studies elucidated the binding mode of iclaprim and suggest reasons for its increased affinity towards mutant DHFR. Iclaprim binds and inhibits the bacterial enzymes in a similar manner to trimethoprim. However, its increased hydrophobic interactions allow for an improved affinity and, unlike trimethoprim, enable the compound to inhibit the F98Y enzyme with nanomolar affinity, thus overcoming the trimethoprim resistance mechanism and remaining a promising and clinically useful inhibitor.
